Table 2.

The targets and biological mechanisms of anti-inflammatory miRNAs for treating atopic dermatitis.

miRNA Code	Targets	Experimental Models	Outcome	Reference
ST-miRCCL22	CCL22	RAW264.7 macrophages and wild-type mice	Reduction of IgE, IL-4, and Th17 cells	Yoon et al. [79]
miR-10a-5p	Hyaluronan synthase 3	Keratinocytes and patients	Inhibition of keratinocyte proliferation and cytokines/chemokines	Vaher et al. [80]
miR-124	RELA (the gene name of p65)	Keratinocytes and patients	Downregulation of IL-8, CCL5, and CCL8	Yang et al. [81]
miR-143	IL-13Rα1	Keratinocytes	Enhancement of the synthesis of filaggrin, loricrin, and involucrin	Zeng et al. [83]
miR-146a	IRAK1 and TRAF6	Keratinocytes	Suppression of TLR2-induced production of TNF-α, IL-8, and CCL20.	Meisgen et al. [85]
miR-146a	CARD10 and IRAK1	Keratinocytes and wild-type and miR-146a−/− mice	Alleviation of chronic skin inflammation through innate immune response suppression in keratinocytes	Rebane et al. [86]
miR-375-3p	YAP1	HaCaT	Inhibition of IL-1β and IL-6 accompanied by a reduction in NF-κ nuclear translocation	Cheng et al. [89]
miR-1294	STAT3	HaCaT, 3D skin equivalent, and wild-type mice	Decrease in inflammation and skin barrier destruction	Chen et al. [90]

CARD10, caspase recruitment domain family member 10; CCL, chemokine (C-C motif) ligand; IgE, immunoglobulin E; IL, interleukin; IRAK1, IL-1 receptor-associated kinase 1; STAT3, signal transducer and activator of transcription 3; ST, Salmonella typhimurium; TLR, Toll-like receptor; TNF-α, tumor necrosis factor-α; TRAF6, tumor necrosis factor receptor-associated factor 6; YAP1, Yes-associated protein 1.